Oyster Point Pharma, Inc.
OYSTDelisted Jan 3, 2023- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001720725
Oyster Point Pharma, Inc. was delisted on Jan 3, 2023; its insiders filed their last Form 4 on Jan 5, 2023; 53 institutions reported holding it in 13F filings for Q4 2022, worth $189.4M in total; no superinvestor held it.
13F holders, Q4 2024
Institutional positions in Oyster Point Pharma, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
OYST is no longer listed, and 13F filings after Q4 2022 list far fewer holders. See Q4 2022
- Institutional holders
- 1
- 0 vs. Q3 2024
- Shares held
- 1
- 0 (0.0%) vs. Q3 2024
- Total value
- $11
- $0 (0.0%) vs. Q3 2024
- New holders
- 0
- 0 more added
- Sold out
- 0
- 0 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting OYST on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1 | $11 |
| Q1 2026 | 1 | $11 |
| Q4 2025 | 1 | $11 |
| Q3 2025 | 1 | $11 |
| Q2 2025 | 1 | $11 |
| Q1 2025 | 1 | $11 |
| Q4 2024 | 1 | $11 |
| Q3 2024 | 1 | $11 |
| Q2 2024 | 1 | $11 |
| Q1 2024 | 1 | $11 |
| Q4 2023 | 1 | $11 |
| Q3 2023 | 1 | $11 |
| Q2 2023 | 1 | $11 |
| Q1 2023 | 1 | $11 |
| Q4 2022 | 53 | $189.4M |
| Q3 2022 | 60 | $112.6M |
| Q2 2022 | 61 | $87.6M |
| Q1 2022 | 72 | $246.2M |
| Q4 2021 | 80 | $378.8M |
| Q3 2021 | 69 | $210.8M |
| Q2 2021 | 58 | $318.3M |
| Q1 2021 | 61 | $335.9M |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Oyster Point Pharma, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Huntington National Bank | 1 | $11 | 0.00% | 00.0% | Unchanged |